Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of the
combination of everolimus with TheraSphere that can be given to patients with advanced NETs
that have spread to the liver. The safety of everolimus and TheraSphere will also be studied.
Everolimus is designed to block a protein inside the cancer cells, which is also involved in
cancer growth.
TheraSphere is a medical device containing a radioactive material called yttrium-90 (Y-90).
Tiny glass beads called microspheres are filled with Y-90 and then injected through an artery
directly into the liver. This allows a large dose of radiation to be given directly to the
tumor, which may lower the risk of side effects from the radiation to other parts of the body
and/or to healthy liver tissue. The radiation from TheraSphere stays in the body and begins
to lose its effect within 12 days. The glass microspheres will stay in the body from that
point on. The radiation will eventually decay (go away). By the time a participant leaves the
hospital, the amount of radiation outside of the body will be low enough to not be a threat
to others.